Aleksei Viktorovich Novik 1,2 , Svetlana Anatolievna Protsenko 3 , Irina Alexandrovna Baldueva 1 , Lev Michailovich Berstein 4 , Vladimir Nikolaevich Anisimov 5 , Irina Nikolaevna Zhuk 6 , Anna Igorevna Semenova 3 , Dilorom Khamidovna Latipova 3 , Elena Viktorovna Tkachenko 6 , Tatiana Yurievna Semiglazova 3 Show Affiliations »
Abstract
LESSONS LEARNED: Melatonin did not increase the efficacy of systemic chemotherapy in melanoma. Metformin did not increase the efficacy of systemic chemotherapy in melanoma. BACKGROUND: Current data support the possibility of antitumor activity of melatonin and metformin. METHODS: From March 2014 to December 2016, 57 patients with disseminated melanoma received dacarbazine (DTIC) 1,000 mg/m2 on day 1 of a 28-day cycle, either as monotherapy (first group) or in combination with melatonin 3 mg p.o. daily (second group) or metformin 850 mg two times a day p.o. daily (third group) as the first-line of chemotherapy. The primary endpoint was objective response rate (ORR). Secondary endpoints were time to progression (TTP), overall survival (OS), immunologic biomarkers, and quality of life. RESULTS: ORR was 7% and did not differ among the treatment groups. Median TTP was 57, 57, and 47 days, respectively, in the first, second, and third groups (р = .362). Median OS was 236, 422, and 419 days, respectively (p = .712). Two patients from the combinations groups showed delayed response to therapy. The increase of CD3+ CD4+ HLA-DR+ lymphocytes (p = .003), CD3+ CD8+ HLA-DR+ (p = .045), CD3+ CD8+ lymphocytes (p = .012), CD4+ CD25high CD127low lymphocytes (p = .029), and overall quantity of lymphocytes (p = .021) was observed in patients with clinical benefit. CONCLUSION: No benefit was found in either combination over DTIC monotherapy. Delayed responses in melatonin and metformin combination groups were registered. The increase of lymphocyte subpopulations responsible for antitumor immune response demonstrates the immune system's potential involvement in clinical activity. © AlphaMed Press; the data published online to support this summary is the property of the authors.
LESSONS LEARNED: Melatonin did not increase the efficacy of systemic chemotherapy in melanoma . Metformin did not increase the efficacy of systemic chemotherapy in melanoma . BACKGROUND: Current data support the possibility of antitumor activity of melatonin and metformin . METHODS: From March 2014 to December 2016, 57 patients with disseminated melanoma received dacarbazine (DTIC ) 1,000 mg/m2 on day 1 of a 28-day cycle, either as monotherapy (first group) or in combination with melatonin 3 mg p.o. daily (second group) or metformin 850 mg two times a day p.o. daily (third group) as the first-line of chemotherapy. The primary endpoint was objective response rate (ORR). Secondary endpoints were time to progression (TTP), overall survival (OS), immunologic biomarkers, and quality of life. RESULTS: ORR was 7% and did not differ among the treatment groups. Median TTP was 57, 57, and 47 days, respectively, in the first, second, and third groups (р = .362). Median OS was 236, 422, and 419 days, respectively (p = .712). Two patients from the combinations groups showed delayed response to therapy. The increase of CD3+ CD4 + HLA-DR+ lymphocytes (p = .003), CD3+ CD8 + HLA-DR+ (p = .045), CD3+ CD8 + lymphocytes (p = .012), CD4 + CD25high CD127low lymphocytes (p = .029), and overall quantity of lymphocytes (p = .021) was observed in patients with clinical benefit. CONCLUSION: No benefit was found in either combination over DTIC monotherapy. Delayed responses in melatonin and metformin combination groups were registered. The increase of lymphocyte subpopulations responsible for antitumor immune response demonstrates the immune system's potential involvement in clinical activity. © AlphaMed Press; the data published online to support this summary is the property of the authors.
Entities: Chemical
Disease
Gene
Species
Keywords:
Dacarbazine; Melanoma; Melatonin; Metformin
Mesh： See more »
Substances： See more »
Year: 2021
PMID： 33749049 PMCID： PMC8100566 DOI： 10.1002/onco.13761
Source DB: PubMed Journal: Oncologist ISSN： 1083-7159